Zurich-based healthtech startup Aeon has raised €8.2 million (US$9 million) in a seed funding round.

The investment was led by the London-based venture capital firm Concentric, with participation from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss angel investor Daniel Gutenberg.

Founded in 2023, Aeon focuses on preventive healthcare. It provides AI-powered check-ups that include whole-body MRI scans, blood biomarker analysis, and genetic testing.

The funding will enable Aeon to expand its operations in Switzerland, Germany, and the UK.

There are plans to open more than 10 new locations.

🔗 Source: EU-Startups

🧠 Food for thought

1️⃣ The preventive care gap represents both a massive health crisis and business opportunity

The chronic disease burden that Aeon aims to address is staggering in scale. In the U.S. alone, 60% of adults have at least one chronic disease, costing over $1 trillion annually in healthcare expenditures 1.

Despite 80% of chronic disease deaths being preventable, only 8% of adults receive all recommended preventive services, highlighting an enormous implementation gap in healthcare delivery 1.

This disconnect creates a substantial market opportunity for companies that can effectively bridge preventive care barriers, particularly those involving comprehensive diagnostics that traditional healthcare systems struggle to deliver efficiently.

The transition from reactive to proactive healthcare that Aeon represents aligns with broader industry evolution documented in medical literature, where advances in molecular biology and technology are enabling more cost-effective preventive strategies 2.

Aeon’s early success in detecting conditions like kidney cancer before symptoms appear demonstrates the tangible impact of this approach, potentially saving both lives and healthcare costs through earlier interventions.

2️⃣ Multi-modal data integration represents the next frontier in preventive medicine

Aeon’s approach of combining full-body MRI, blood biomarkers, and genetic testing reflects an emerging understanding that single-source diagnostics are insufficient for comprehensive risk assessment.

Stanford Medicine’s research shows that integrating multiple data sources dramatically improves diagnostic accuracy and predictive capabilities, as demonstrated in their 400,000-participant Apple Watch study focused on atrial fibrillation detection 3.